WO2004017938A3 - Nitrofurantoin controlled release dosage form - Google Patents

Nitrofurantoin controlled release dosage form Download PDF

Info

Publication number
WO2004017938A3
WO2004017938A3 PCT/IB2003/003517 IB0303517W WO2004017938A3 WO 2004017938 A3 WO2004017938 A3 WO 2004017938A3 IB 0303517 W IB0303517 W IB 0303517W WO 2004017938 A3 WO2004017938 A3 WO 2004017938A3
Authority
WO
WIPO (PCT)
Prior art keywords
nitrofurantoin
dosage form
controlled release
release dosage
release portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2003/003517
Other languages
French (fr)
Other versions
WO2004017938A2 (en
Inventor
Puneet Sharma
Pananchukunnath Manoj Kumar
Vishnubhotla Nagaprasad
Sunilendu Bhushan Roy
Rajiv Malik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ranbaxy Laboratories Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Priority to US10/525,534 priority Critical patent/US20060002997A1/en
Priority to AU2003255890A priority patent/AU2003255890A1/en
Priority to MXPA05002136A priority patent/MXPA05002136A/en
Priority to BR0313745-7A priority patent/BR0313745A/en
Priority to EP03792571A priority patent/EP1635794A2/en
Publication of WO2004017938A2 publication Critical patent/WO2004017938A2/en
Publication of WO2004017938A3 publication Critical patent/WO2004017938A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention generally relates to controlled release dosage forms which provide immediate release and sustained release of nitrofurantoin, and processes for their preparation. The controlled release dosage form includes a sustained release portion and an immediate release portion. The sustained release portion includes nitrofurantoin and one or more pH dependent hydrophilic polymers. The immediate release portion includes nitrofurantoin.
PCT/IB2003/003517 2002-08-23 2003-08-25 Nitrofurantoin controlled release dosage form Ceased WO2004017938A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/525,534 US20060002997A1 (en) 2002-08-23 2003-08-25 Nitrofurantoin controlled release dosage form
AU2003255890A AU2003255890A1 (en) 2002-08-23 2003-08-25 Nitrofurantoin controlled release dosage form
MXPA05002136A MXPA05002136A (en) 2002-08-23 2003-08-25 Nitrofurantoin controlled release dosage form.
BR0313745-7A BR0313745A (en) 2002-08-23 2003-08-25 Nitrofurantoin controlled release pharmaceutical presentation and preparation process
EP03792571A EP1635794A2 (en) 2002-08-23 2003-08-25 Nitrofurantoin controlled release dosage form

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN860DE2002 2002-08-23
IN860/DEL/2002 2002-08-23

Publications (2)

Publication Number Publication Date
WO2004017938A2 WO2004017938A2 (en) 2004-03-04
WO2004017938A3 true WO2004017938A3 (en) 2004-05-13

Family

ID=31898452

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/003517 Ceased WO2004017938A2 (en) 2002-08-23 2003-08-25 Nitrofurantoin controlled release dosage form

Country Status (6)

Country Link
US (1) US20060002997A1 (en)
EP (1) EP1635794A2 (en)
AU (1) AU2003255890A1 (en)
BR (1) BR0313745A (en)
MX (1) MXPA05002136A (en)
WO (1) WO2004017938A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257726B2 (en) * 1997-09-26 2012-09-04 Abbott Laboratories Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices
US8057816B2 (en) * 1997-09-26 2011-11-15 Abbott Laboratories Compositions and methods of administering paclitaxel with other drugs using medical devices
EP1675550A4 (en) * 2003-09-24 2007-10-10 Combinatorx Inc Therapeutic regimens for administering drug combinations
US20050202079A1 (en) * 2004-03-15 2005-09-15 Mylan Pharmaceuticals Inc. Novel orally administrable formulation of nitrofurantoin and a method for preparing said formulation
MX2007007836A (en) 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Method for stabilizing anti-dementia drug.
CN101166543B (en) * 2005-04-28 2014-07-16 卫材R&D管理有限公司 Composition containing anti-dementia drug
CN102000041A (en) * 2010-11-19 2011-04-06 合肥合源药业有限公司 Furadantin capsule containing quick-release component and slow-release component and preparation method thereof
KR101974412B1 (en) * 2018-02-28 2019-05-02 보령제약 주식회사 Pharmaceutical formulation and preparation method thereof
EP4285895A1 (en) * 2022-06-03 2023-12-06 Adalvo Limited Nitrofurantoin oral dosage form

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
US4370313A (en) * 1981-10-26 1983-01-25 Eaton Laboratories, Inc. Nitrofurantoin dosage form
EP0250023A1 (en) * 1986-06-16 1987-12-23 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
US4777033A (en) * 1985-06-11 1988-10-11 Teijin Limited Oral sustained release pharmaceutical preparation
US20010048944A1 (en) * 2000-02-24 2001-12-06 Rudnic Edward M. Antibiotic product, use and formulation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3401221A (en) * 1964-08-25 1968-09-10 Norwich Pharma Co Treatment of urinary tract infection
IT1255522B (en) * 1992-09-24 1995-11-09 Ubaldo Conte COMPRESSED FOR THERAPEUTIC USE SUITABLE FOR SELLING ONE OR MORE ACTIVE SUBSTANCES WITH DIFFERENT SPEEDS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
US4370313A (en) * 1981-10-26 1983-01-25 Eaton Laboratories, Inc. Nitrofurantoin dosage form
US4777033A (en) * 1985-06-11 1988-10-11 Teijin Limited Oral sustained release pharmaceutical preparation
EP0250023A1 (en) * 1986-06-16 1987-12-23 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
US20010048944A1 (en) * 2000-02-24 2001-12-06 Rudnic Edward M. Antibiotic product, use and formulation thereof

Also Published As

Publication number Publication date
WO2004017938A2 (en) 2004-03-04
BR0313745A (en) 2005-07-12
AU2003255890A8 (en) 2004-03-11
MXPA05002136A (en) 2005-06-03
US20060002997A1 (en) 2006-01-05
AU2003255890A1 (en) 2004-03-11
EP1635794A2 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
WO2005086776A3 (en) Posterior process dynamic spacer
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2004062577A3 (en) Two or more enteric materials to regulate drug release
EP1129693A3 (en) Composition for inhibiting body odor and uses thereof
AU2003258308A1 (en) Ph triggered targeted controlled release systems
WO2004045464A3 (en) Medical devices
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
MXPA05003215A (en) Coated chewing gum.
WO2003097794A3 (en) Universal-tagged oligonucleotide primers and methods of use
WO2003093322A3 (en) Carrageenan based antimicrobial compositions
WO2005117919A3 (en) Delayed-setting calcium phosphate pastes
EP1406122A3 (en) Photosensitive composition and acid generator
WO2006002840A8 (en) Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant
WO2004017938A3 (en) Nitrofurantoin controlled release dosage form
WO2002073208A3 (en) Anti-epileptogenic agents
WO2003033557A3 (en) Copolymers containing fluorine, method for the production and use thereof
AU2002323873A1 (en) Active ingredient combination of E.G. galanthamine or deoxypeganine and E.G. acamprosate or memantine for treating an addiction such as alcoholism
WO2005007074A3 (en) Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
ZA200203180B (en) Method for preventing dyskinesias.
WO2003079962A3 (en) Assembled unit consisting of individually separable transdermal therapeutic systems
WO2002060906A8 (en) Crystal modification of olanzapine
WO2006034035A3 (en) Treatment of ischemia
WO2002047664A3 (en) Microparticles with an improved release profile and method for the production thereof
AU2003201163A1 (en) Method for the preparation of lariciresinol, cyclolariciresinol and secoisolariciresinol
WO2003034985A3 (en) Telomerase interference

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/002136

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2006002997

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10525534

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003792571

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1159/DELNP/2005

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 10525534

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003792571

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003792571

Country of ref document: EP